D. Erlanson

Nature reviews. Drug discovery · 2016–2019

A researcher in the Science corpus: 2 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Whom D. Erlanson trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. M. Hann
  2. Michael A. Walters
  3. A. Hopkins

Papers from D. Erlanson's perspective

Ordered by how strongly the researchers D. Erlanson trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Ligand efficiency: a useful metric for lead selection. (Drug Discovery Today)
  2. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State. (Cancer Discovery)
  3. An inhibitor of Bcl-2 family proteins induces regression of solid tumours (Nature)
  4. A 'rule of three' for fragment-based lead discovery?
  5. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets (Nature Medicine)
  6. Crystal structure of the human β2 adrenergic G-protein-coupled receptor
  7. The role of ligand efficiency metrics in drug discovery
  8. Molecular Interaction Studies Using Microscale Thermophoresis (Assay and drug development technologies)
  9. Vemurafenib: the first drug approved for BRAF-mutant cancer (Nature reviews. Drug discovery)
  10. Structure of a β1-adrenergic G protein-coupled receptor (Nature)

Their papers